Eli Lilly buys company for $7B to hedge GLP-1 revenue drop-off
The deal is framed as diversification away from dependence on the incretin franchise that dominates Lilly's sales.
TR
By Tom Reyes · Markets Editor
Apr 20 03:00 ETSource: Yahoo Finance
The wire
- 01Eli Lilly has struck a $7 billion acquisition described as a hedge against an eventual decline in GLP-1 revenue.
- 02Lilly's incretin franchise drives the bulk of company sales, so capital allocation away from it signals how management views long-term obesity market competition.
- 03Details of the target, deal terms and closing conditions were not available in the item beyond the headline figure.
From the source
Read at finance.yahoo.comEli Lilly hedges against GLP-1 revenue drop-off with $7B acquisition
